NEW YORK (GenomeWeb News) – Sygnis Pharma today said that it has licensed to Qiagen rights to distribute a new amplification buffer for isothermal amplification.
Sygnis, which is based in both Madrid, Spain and Heidelberg, Germany, said that the new buffer, which is used in isothermal amplification, was developed in the lab of Margarita Salas at the Center for Molecular Biology - Severo Ochoa, Autonomous University of Madrid/ Spanish National Research Council (CSIC). Terms of the agreement were not disclosed.
The deal is the second signed between Sygnis and Qiagen over the past year. Last July, Sygnis inked an exclusive global license with Qiagen for distribution of its polymerase QualiPhi, an updated version of the phi 29 DNA polymerase.